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Diabetic nephropathy (DN) is a major complication associated with both type 1 and
type 2 diabetes, and a leading cause of end-stage renal disease. Conventional
therapeutic strategies are not fully efﬁcacious in the treatment of DN, suggesting an
incomplete understanding of the gene regulation mechanisms involved in its patho-
genesis. Furthermore, evidence from clinical trials has demonstrated a ‘‘metabolic
memory’’ of prior exposure to hyperglycemia that continues to persist despite
subsequent glycemic control. This remains a major challenge in the treatment of DN
and other vascular complications. Epigenetic mechanisms such as DNA methylation,
nucleosomal histone modiﬁcations, and noncoding RNAs control gene expression
through regulation of chromatin structure and function and post-transcriptional
mechanisms without altering the underlying DNA sequence. Emerging evidence
indicates that multiple factors involved in the etiology of diabetes can alter epigenetic
mechanisms and regulate the susceptibility to diabetes complications. Recent studies
have demonstrated the involvement of histone lysine methylation in the regulation of
key ﬁbrotic and inﬂammatory genes related to diabetes complications including DN.
Interestingly, histone lysine methylation persisted in vascular cells even after with-
drawal from the diabetic milieu, demonstrating a potential role of epigenetic
modiﬁcations in metabolic memory. Rapid advances in high-throughput technologies
in the ﬁelds of genomics and epigenomics can lead to the identiﬁcation of genome-
wide alterations in key epigenetic modiﬁcations in vascular and renal cells in diabetes.
Altogether, these ﬁndings can lead to the identiﬁcation of potential predictive
biomarkers and development of novel epigenetic therapies for diabetes and its
associated complications.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Diabetes and metabolic disorders have reached epidemic
proportions worldwide and are major risk factors for several
long-term complications, including progressive renal failure and
chronic kidney disease, termed diabetic nephropathy (DN). More
than 40% of patients with diabetes progress to DN, a major cause
of end-stage renal disease (ESRD). In addition, patients with DN
are more susceptible to macrovascular diseases such asrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
tes, Beckman Research Institu
jan).atherosclerosis, hypertension, and stroke, leading to a higher
mortality rate among diabetic patients with ESRD than among
those without ESRD. DN is pathologically characterized by renal
glomerular hypertrophy, expansion of mesangial and tubular
compartments, accumulation of extracellular matrix in multiple
renal cells, inﬂammatory cell inﬁltration, and podocytopenia
associated with foot process effacement. These factors lead toublished by Elsevier. This is an open access article under the CC BY-NC-
te of City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.
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dysfunction. Clinically, DN is identiﬁed by albuminuria, rising
creatinine levels, and aberrant glomerular ﬁltration rates. Signal
transduction mediated by key factors associated with diabetes,
such as high glucose (HG), advanced glycation end products
(AGEs), oxidized lipids, proinﬂammatory cytokines, and local
growth factors including transforming growth factor-b1 (TGF-b)
and angiotensin II (Ang II), can lead to renal hypertrophy and
ﬁbrosis through various biochemical mechanisms [1–6].
Several treatment strategies are available to cure DN or
reduce its progression. These include modalities used to
suppress the renin–angiotensin–aldosterone system and con-
trol blood glucose levels. However, diabetic patients are still
reaching ESRD at an alarming rate. Moreover, clinical and
experimental studies have shown that the risk and severity of
diabetic complications, including DN, seem to persist even
after glucose normalization, suggesting a ‘‘metabolic mem-
ory’’ of the prior exposure to HG [7,8]. These ﬁndings imply
that the current knowledge based on biochemical mechan-
isms, genetics, and proteomics research [6,9–12] does not
explain the pathophysiology of DN completely. More than a
decade after the human genome has been sequenced, it is
becoming increasingly clear that changes in the DNA
sequence and genetic mutations alone cannot fully explain
the diversity of cellular responses and disease incidence in the
general population. On the other hand, epigenetic mechan-
isms in chromatin can also regulate gene expression, cellular
identity, phenotypic variations, and disease states without
any alterations in the underlying DNA sequence. Epigenetics
can be inﬂuenced profoundly by diet, lifestyle, and the
environment—key factors associated with the etiology of
diabetes [13,14]. Thus, complex interactions between genes
and the environment can play signiﬁcant roles in common
human diseases such as diabetes and related pathologies.
Given the high incidence and debilitating nature of DN, it is
imperative to evaluate additional mediatory factors and
therapeutic targets. The current review focuses on epigenetics
and the emerging evidence for epigenetic mechanisms in
diabetes and its complications, with special emphasis on DN.Epigenetics
The term ‘‘epigenetics’’ originally referred to the pro-
grammed changes during development that cannot be
explained by conventional genetics [15]. Epigenetics typically
refers to changes in gene expression and phenotype, including
those conferred mitotically or meiotically, that occur without
any alterations in the underlying DNA sequence. More recently,
epigenetics is deﬁned as ‘‘the structural adaptation of chromo-
somal regions so as to register, signal, or perpetuate altered
activity states’’ to account for alterations in the chromatin state
[15,16]. Epigenetic signals regulate gene expression through
chromatin remodeling, which in turn regulates chromatin
structure and access to transcription factors and coregulators.
Epigenetic control of gene regulation plays an important role in
embryogenesis, cellular differentiation and development, cell
identity, genomic imprinting, immune cell function, stem cell
plasticity, transcriptional memory, and cellular responses to
environmental signals [17–19]. Poor dietary choices and expo-
sure to environmental pollutants can regulate epigenetic
mechanisms to induce abnormal metabolic phenotypes that
can be further compounded by genetic susceptibility [14,20].Furthermore, environmentally induced epigenetic modiﬁca-
tions could lead to phenotypic changes that persist even long
after the original exposure was removed. Several studies also
demonstrated the transgenerational inheritance of epigenetic
changes, thus highlighting the potential effect of maternal
malnutrition or overnutrition on the fetus that can result in
deleterious effects later in adult life, including predisposition to
diabetes and associated complications [13,21,22]. However,
whether low birth weight increases the risk for DN is still not
clear [23]. Furthermore, while the role of genetic factors
associated with DN has been examined extensively, the role
of epigenetics is only recently being considered.Epigenetic modiﬁcations in chromatin
and the epigenome
Chromatin, the site of epigenetic modiﬁcations in the nucleus,
is composed of chromosomal DNA tightly packaged into repeat-
ing units called nucleosomes. Each nucleosome is made up of 146
bp DNA, which is wrapped around an octamer protein complex
consisting of dimers of core histone proteins H2A, H2B, H3, and
H4 held together by a linker histone H1 [24]. Chromatin structure
is dynamically regulated by epigenetic modiﬁcations between
transcriptionally silent ‘‘heterochromatin’’ and active ‘‘euchroma-
tin’’ states (Fig. 1). These include covalent post-translational
modiﬁcations (PTMs) of nucleosomal histones as well as DNA
methylomes (DNAMes), while noncoding RNAs such as micro-
RNAs can also regulate gene expression by post-transcriptional
epigenetic mechanisms. Epigenetic modiﬁcations provide dock-
ing sites for proteins/enzymes that alter chromatin structure,
remodel nucleosomes, and erase or recruit other transcription
regulators. Combinatorial effects of epigenetic modiﬁcations on
promoters, enhancers, and other regulatory elements of the
genome dictate gene expression patterns and the resultant
phenotypes under normal and pathophysiological conditions
[20,21,25]. Genome-wide patterns of these modiﬁcations collec-
tively form the ‘‘epigenome,’’ which is cell-type speciﬁc, can be
modulated by environmental cues, and can lead to aberrant gene
expression associated with human diseases [13,20,26].
DNAMe, the most highly studied epigenetic modiﬁcation,
generally takes place on cytosines of CpG dinucleotides in
regions known as ‘‘CpG’’ islands located in chromosomal DNA.
DNAMe is catalyzed by DNA methyltransferases (DNMTs) that
transfer methyl group from S-adenosyl-methionine to the 50
position of cytosine (50-methyl cytosine). In mammalian cells,
DNMT3A and DNMT3B mediate de novo methylation while
DNMT1 acts as a maintenance methyl transferase [18]. Pro-
moter DNAMe generally leads to gene silencing via multiple
mechanisms including inhibition of transcription factor bind-
ing, increasing nucleosome occupancy at transcriptional start
sites, regulation of histone PTMs and chromatin remodeling,
cross-talk with histone methyltransferases, acetylases and
deacetylases, and recruitment of methyl binding proteins such
as MeCP2 [18,27]. Similar to other epigenetic modiﬁcations,
DNAMe is now also known to be reversible [28,29]. Non-CpG
methylation has also been found in pluripotent
cells such as embryonic stem cells or early embryos [30,31],
but it is not common in adult somatic tissues [32]. Although
the role of non-CpG island methylation in mammals is largely
unknown, recent studies have shown that it may also promote
gene silencing and contribute to tumorogenesis [33]. DNAMe
regulates important biological processes such as imprinting,
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Figure 1. Chromatin structure and function. Chromatin is made up
of repeating units of nucleosomes consisting of 146 bp DNA wrapped
around dimers of four histone proteins (H2A, H2B, H3, and H4). The
exposed amino-terminal tails of nucleosomal histones are subjected to
post-translational modiﬁcations. Combinatorial effects of histone mod-
iﬁcations and DNAMe regulate the chromatin structure between
transcriptionally silent ‘‘heterochromatin’’ and active ‘‘euchromatin.’’
Enrichment of promoter DNAMe and histone modiﬁcations such as
H3K9me3, H3K27me3, and H4K20me3 promote nucleosome conden-
sation to repress transcription (heterochromatin). On the other hand,
histone modiﬁcations H3 or H4 KAc (H3/H4KAc) and H3K4me promote
open chromatin formation and increase accessibility to the transcrip-
tion machinery, leading to active transcription (euchromatin). Other
histone modiﬁcations such as Ser/Thr phosphorylation, ubiquitination
and SUMOylation, and non-coding RNAs including microRNAs also
regulate chromatin structure and function (not shown). Genome-wide
patterns of DNAMe and histone modiﬁcations are referred to as the
‘‘epigenome.’’ Its response to internal and external signals regulates
gene expression involved in diverse biological processes and disease
conditions. DNAMe, DNA methylomes; KAc, lysine acetylation.
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studied extensively because gene silencing of tumor suppres-
sors and cell-cycle regulators via promoter hypermethylation
has been associated with several cancers. Key epigenetic
therapies based on DNAMe inhibitors have been developed
for cancer [34,35]. However, relatively less is known about the
role of DNAMe in diabetes and its complications.
PTMs at chromatin histones also confer epigenetic changes in
a dynamic fashion. Histone PTMs include lysine acetylation
(KAc), lysine methylation (KMe), arginine methylation, serine/
threonine phosphorylation, SUMOylation, Adenosine dipho-
sphate (ADP)-ribosylation, and ubiquitination (Table 1) [17,25].
In general, the amino acid residues in the exposed amino-
terminal tails of nucleosomal histones are subjected to these
PTMs; some PTMs within globular domain of histones have also
been identiﬁed. Histone PTMs act in concert with each other,
and this ‘‘histone code’’ can dictate gene transcription [17,25].
Histone lysine acetylation (HKAc) and methylation (HKme) are
the best studied and will be discussed in this review. HKAc is
mediated by histone acetyltransferases (HATs) and removed by
histone deacetylases (HDACs). On the other hand, histone lysine
methyltransferases (HMTs) mediate KMe and are erased by
histone lysine demethylases (HDMs). Recently, these enzymes
have been renamed as lysine acetyltransferases, lysine methyl-
transferases, and lysine demethylases, because they can also
modify lysines in nonhistone proteins [37].
Histone modiﬁcations such as H3K9/14 or H4K12/16
acetylation at gene promoters and enhancers are generallyepigenetic marks for active gene transcription. HKAc is
mediated by HATs such as CBP/p300 and SRC-1, which also
act as coactivators. Acetylation of lysine residues in histone
tails neutralizes the positive charge and destabilizes interac-
tions between histones and DNA as well as nucleosome–
nucleosome interactions. In addition, the acetylated residues
act as docking sites for chromatin remodeling proteins, lead-
ing to chromatin relaxation and increased accessibility to the
transcription machinery. HATs are quite nonselective and
acetylate several lysine residues in both histone and non-
histone proteins [17,38]. However, proﬁling approaches such
as chromatin immunoprecipitation followed by next-
generation DNA sequencing (ChIP-Seq) revealed differences
in the genome-wide distribution of individual HATs [39].
Genome-wide approaches also showed that enhancers are
usually associated with CBP and p300 along with histone
lysine monomethylation (H3K4me1) [40–42].
HDACs remove HKAc marks and mediate gene repression.
They are subdivided into four classes, I–IV, depending on their
structure, function, and mode of action. HDACs restore the
positive charge of histone lysines and promote chromatin
condensation, resulting in decreased chromatin access and
reduced rates of transcription. HDACs have multiple func-
tions, which can be attributed to their low substrate speciﬁ-
city. Their actions can be regulated at the level of both gene
expression and promoter-speciﬁc recruitment [43]. Studies in
knockout mice revealed speciﬁc functions of HDACs in vivo,
including embryonic stem cell differentiation and cardiovas-
cular effects [44–46]. The function of HDAC in cancer cells has
been studied extensively, and several HDAC regulators are
being used to treat cancers [35,47].
HKme is very interesting since it can be associated with
either active or repressed genes depending on the modiﬁed
lysine residue (Table 1). Furthermore, lysine residues can be
mono (me1), di (me2), or tri (me3) methylated, adding another
level of complexity. H3K4me, H3K36me, and H3K79me are
usually associated with active promoters and gene bodies,
while H3K9me, H3K27me, and H4K20me promote transcrip-
tion repression. In contrast, demethylation of H3K4me can
inhibit transcription, whereas demethylation of H3K9me,
H3K27me, and H4K20me marks can increase transcription.
HMTs generally contain a SET domain that catalyzes methyl-
transferase activity, whereas demethylation activity in HDMs is
mediated by amine oxidase-like domains or JmjC domains
[25,48]. HMTs and HDMs are highly speciﬁc to the lysine
residue being modiﬁed and also to the extent of methylation,
e.g., SUV39H1 can mediate H3K9me3 but not H3K9me1, Ezh2
mediates H3K27me3, and SET7/9 mediates H3K4me1/me2. On
the other hand, lysine-speciﬁc demethylase 1 (LSD1), the ﬁrst
HDM to be identiﬁed, can erase H3K4me1/me2, while the
JARID1 family of demethylases removes H3K4me3. Jmjd2a can
erase both H3K9me3 and H3K36me3, while Jmjd3 is speciﬁc to
H3K27me3 [17,49] (Table 1). Recent high-throughput proﬁling
of various histone PTMs associated with promoters, enhancers,
and insulators led to the identiﬁcation of such key regulatory
elements genome wide [25,42,50,51]. Transcription start sites
and promoters are enriched with H3K4me3 and H3K9/14Ac,
enhancers with H3K4me1, and gene bodies of actively tran-
scribed genes with H3K36me3. Histone modiﬁcations at
enhancers also confer tissue- and cell-speciﬁc transcription in
conjunction with lineage- or cell-speciﬁc transcription factors
[25,42,52,53]. Histone modiﬁcations can also cross-talk with
each other to regulate gene expression. Thus, H3K27me3 and
Table 1. Histone modiﬁcations and their function in the transcription regulation*
Modiﬁcation Histone Modifying enzyme Proposed function
Acteylation H2A, H3, H4 ATF2, ELP3, GCN5, GTF3C4, HAT1, MORF,
MOZ, p300, PCAF, SRC-1, TAF1, Tip 60
Activation
Deacetylation H2A, H3, H4 HDAC1–HDAC11, SIRT1–SIRT7 Repression
Methylation H1K26, H3K27 Ezh2 Repression
H3K9 ESET, G9a, SUV39H1, SUV39H2, SETDB1 Repression
H3K4 MLL, SET7, SET9, SMYD3 Activation
H3K36 SETD2, NSD1 Activation
H3K79 DOT1L Activation
H4K20 PR-SET7, SUV4-20H1, SUV4-20H2 Repression
H3R17 CARM1 Activation
H4R3 PRMT1 Activation
H3R8 PRMT5 Repression
H4R3 PRMT5 Repression
Demethylation H3K4 LSD1 Repression
H3K4 JARID1A, JARID1B, JARID1C, JARID1D Repression
H3K9 JMJD1A Activation
H3K9/H3K36 JMJD2A, JMJD2B, JMJD2C, JMJD2D Activation/Repression
H3K36 JHDM1A, JHDM1B Repression
H3K27 JMJD3, UTX Activation
Phosphorylation H2AS1, H3S10, H3S28 MSK1 Repression
H3S10 Aurora-B, IKK-a, MSK2, RSK2 Activation
H2AS1, H2AS139, H4S1 ATR, ATM, DNA-PK, CK2, Tel1 DNA repair
Ubiquitylation H2AK119 RING1B Activation/repression
H2BK120 UbcH6 Activation/repression
Biotinylation H2AK9, H2AK13, H3K4,
H3K9, H3K18, H4K12
Biotinidase Activation
n References [17,20,36].
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these bivalent modiﬁcations play important roles in stem cell
differentiation [54]. H3K9Ac and Ser10 phosphorylation gen-
erally inhibit H3K9me to promote gene expression [17]. Cross-
talk between histone PTMs and DNAMe has also been docu-
mented. DNAMe acts in concert with repressive histone mod-
iﬁcations such as H3K9me3 to recruit transcription repressors
and silence gene expression [20,55].
Regulation of histone-modifying enzymes plays a critical
role in gene expression involved in key biological processes
including differentiation, cancer, and diabetes and its compli-
cations [7,8,20,34,36,56,57]. In general, HKme is relatively
more stable compared with other histone modiﬁcations. There-
fore, similar to DNAMe, H3Kme might be involved in the
inheritance of epigenetic signatures to confer transcriptional
memory that lasts long even after the removal of physiological
or pathological signals. Polycomb repressive complex (PRC)
proteins, which mediate the repressive H3K27me3 mark,
remained tightly bound to chromatin during DNA replication,
indicating a potential epigenetic role for such histone marks in
the maintenance of transcription memory or epigenetic trans-
mission [58,59]. Thus, alterations in HKme may contribute to
the metabolic memory of transcription and persistent expres-
sion of pathologic genes implicated in diabetic complications
[8,57]. As discussed earlier, epigenetic marks altered by the
environment can be inherited during both somatic and germ
cell replications [60]. Evidence shows that DNAMe plays an
important role in transgenerationally inherited obesity [61]. In
addition, high-fat diets have been found to promote transge-
nerational transmission of adult-onset metabolic diseases in
mice, suggesting an underlying epigenetic mechanism [62]. In
epigenetic transmission, the role of DNAMe is more apparent
than that of histone modiﬁcations, although evidence also
exists for the latter via PRCs and histone recycling [59,63].
In general, compared to genetic transmission, epigenetictransmission is more complex and needs further investigation,
especially in the ﬁeld of diabetes and its complications.Metabolic memory and diabetes complications
Hyperglycemia has been implicated in the development of
numerous diabetic complications including nephropathy.
Patients with both type 1 diabetes (T1D) and type 2 diabetes
(T2D) continue to be at higher risk for developing complica-
tions even several years after achieving normoglycemia.
This phenomenon of ‘‘metabolic memory’’ was clearly demon-
strated in clinical trials such as the Diabetes Control and
Complications Trial (DCCT) and the follow-up Epidemiology
of Diabetic Interventions and Complications (EDIC) study
[7,8,64]. The DCCT showed that intensive insulin therapy
to attain strict glycemic control in T1D patients led to
much better control of various vascular complications than
conventional therapy [65]. Subsequently, both standard and
intensive treatment DCCT groups were placed on intensive
insulin therapy and followed up long term in EDIC study.
Interestingly, EDIC study showed that those previously
assigned to standard/conventional therapy in DCCT continued
to develop complications, such as nephropathy and retino-
pathy, at signiﬁcantly higher rates than the previous intensive
therapy group in DCCT [66]. Recent reports demonstrate
continued protection and lower rates of cardiac, renal, and
retinal complications; lower blood pressure; more favorable
lipid proﬁles; and reduced long-term risk for impaired glo-
merular ﬁltration rate (GFR) in the former DCCT intensive
therapy group [67–70]. Other clinical trials in T2D patients
also demonstrated that a similar memory phenomenon,
termed ‘‘legacy effect,’’ in those with lower fasting blood
glucose and strict glycemic control resulted in lower rates of
vascular complications [71–73]. These studies clearly
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Figure 2. Diabetic nephropathy and metabolic memory. Signal
transduction mediated by factors associated with the diabetic milieu
(HG, AGEs, growth factors, and oxidized lipids) induces alterations in
epigenetic modiﬁcations (histone PTMs and DNAMe) and changes in
chromatin remodeling. This leads to pathologic gene expression
(inﬂammatory genes and ﬁbrotic genes) in collaboration with key TFs
in monocytes/macrophages, vascular and renal cells. Persistence of
these epigenetic modiﬁcations even after normalizing glucose levels
can play an important role in ‘‘metabolic memory’’ and gene expres-
sion implicated in long-lasting diabetic complications including
nephropathy. AGEs, advanced glycation end products; DNAMe, DNA
methylomes; EC, endothelial cell; GF, growth factor; HG, high glucose;
Ox lipids, oxidized lipids; PTM, post-translational modiﬁcation; TF,
transcription factor.
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fact that a memory of prior exposure to hyperglycemia might
play a signiﬁcant role in the subsequent risk of diabetic
complications including nephropathy. However, mechanisms
of metabolic memory are not clear and remain a major
obstacle in the prevention or treatment of diabetic complica-
tions. As discussed later, recent studies have evaluated a role
for epigenetic mechanisms in metabolic memory.
Several experimental cell culture and animal models have
been developed to understand the mechanisms involved in
metabolic memory. Endothelial cells (ECs) cultured in HG for
short time periods continued to exhibit enhanced oxidative
stress, and proﬁbrotic and inﬂammatory genes even after
return to normal glucose [74–76]. Vascular smooth muscle
cells (VSMC) derived from the aortas of T2D db/db mice
exhibited enhanced proinﬂammatory responses even after
culturing ex vivo for a few weeks [77,78]. In T1D dogs, islet
transplantation performed 12 weeks after the development of
diabetes did not prevent progression to retinopathy, com-
pared to that after 6 weeks [79]. Similarly, in T1D rats,
reinstitution of glycemic control following several weeks of
poor glycemic control did not reverse inﬂammation or pro-
gression to retinopathy and nephropathy [80–83]. Thus, both
clinical and experimental evidences suggest that prior expo-
sure to hyperglycemia can have long-lasting deleterious
effects even after subsequent glycemic control. Other related
factors associated with hyperglycemia and diabetes such as
AGEs may also contribute to metabolic memory, because
AGEs can modify various cellular proteins and enzymes to
cause long-lasting changes in their functions, or can activate
multiple signaling pathways via the receptor for AGE (RAGE)
to induce inﬂammatory genes [84,85]. Furthermore, dyslipi-
demia and insulin resistance associated with T2D may also be
involved. It is likely that these factors acting independently or
cumulatively can lead to changes in epigenetic histone PTMs
and DNAMe in target cells, thus contributing to metabolic
memory (Fig. 2).DNAMe and diabetes complications
DNAMe is the most stable and heritable epigenetic mod-
iﬁcation and is known to play an important role in normal as
well as pathophysiological processes. However, its involve-
ment in diabetes and its complications is less well studied.
Early studies with mouse models showed that regulation of
the Agouti gene by DNAMe plays a key role in the develop-
ment of coat color, diabetes, and obesity. Interestingly, these
studies also demonstrated the inﬂuence of external factors
such as maternal diet on epigenetic processes and the
transgenerational inheritance of DNAMe [60,86]. In a model
of intrauterine growth retardation (IUGR) in rats, it was found
that the development of diabetes was associated with pro-
moter hyper-DNAMe and inhibition of the islet-speciﬁc tran-
scription factor Pdx1 that regulates insulin gene expression in
pancreatic b cells. DNAMe was also found to be related to
downregulation of peroxisome proliferator-activated recep-
tor-gamma coactivator 1a (PGC-1a) and Igf1r in pancreatic
islets and skeletal muscles of T2D animals and patients
[87–89]. PGC-1a downregulation led to the inhibition of
insulin expression and mitochondrial biogenesis [87,88].
Furthermore, in another study, insulin promoter DNAMe in
islets of T2D patients was correlated with lower insulin levelsand elevated HbA1c levels [90]. Another recent study on
monozygotic twins reported a 10% increase in global DNAMe
at Alu repetitive elements in peripheral blood leukocytes,
which showed signiﬁcant correlation with insulin resistance
[91]. Genetic association studies have identiﬁed single nucleo-
tide polymorphisms in the fat mass and obesity-associated
(FTO) gene region with a risk of adiposity. Functional studies
showed that FTO controls feeding behavior and energy expen-
diture [92]. Interestingly, recent studies in T2D patients showed
a small but signiﬁcant decrease in DNAMe at a CpG site in the
ﬁrst intron of the FTO gene [93]. Furthermore, this hypomethy-
lation was also observed in healthy individuals who later
progressed to impaired glucose metabolism. These unique
ﬁndings suggest a correlation between epigenetic DNAMe
variations and predisposition to T2D [93].
Studies, reported to date, investigating kidneys of diabetic
animal models or renal cells treated in vitro with HG have not
demonstrated signiﬁcant changes in DNAMe [94–96]. On the
other hand, whole blood genomic DNA from T1D patients
with DN exhibited differential DNAMe patterns at 19 genes
including UNC13B, relative to those without nephropathy [97].
Interestingly, UNC13B was correlated with DN in genetic
studies, suggesting an association between DNAMe and DN
susceptibility. Several differentially methylated genes were
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compared to patients with chronic kidney disease who did not
progress to ESRD [98]. However, relevance of these ﬁndings to
DN awaits further investigation. It is likely that high-
throughput approaches using genomic DNA and target tissue
biopsies from various clinical cohorts or animal models will
clarify the relationship between DNAMe and diabetic compli-
cations including nephropathy. In this connection, it is note-
worthy that a recent genome-wide proﬁling study using next-
generation sequencing demonstrated signiﬁcant changes in
DNAMe in HG-treated ECs at several genes related to diabetes
and its complications. Reciprocal relations with histone acet-
ylation were also demonstrated [99].Histone modiﬁcations, diabetes complications, and
metabolic memory
Progress in the study of histone PTMs has grown by leaps
and bounds in the ﬁeld of cancer. However, it is still in its
infancy in the ﬁeld of diabetes. Recent studies have shed some
insights into the role of histone modiﬁcations in diabetes,
diabetic complications, and metabolic memory. Histone PTMs
have been implicated in the regulation of insulin expression by
Pdx1 in pancreas. In response to elevated glucose levels, Pdx1
could recruit the HAT coactivator p300 and HMT SET7 to the
insulin promoter, which could promote chromatin relaxation
by increasing H3K9/14Ac and H3K4me1/2, respectively, to
enhance insulin transcription. In contrast, Pdx1 could recruit
HDACs to inhibit insulin expression when glucose levels were
low [100–102]. Interestingly, it was found that IUGR reduces
insulin gene expression by inhibiting Pdx1 expression via
alterations in promoter H3KAc, H3K4me3, and DNAMe in the
offspring [103]. H3K9me2 and H3K4me2, as well as the related
enzymes SETDB1 (H3K9 methyl transferase) and LSD1 (H3K4
demethylase), were reported to play critical roles in adipocyte
differentiation [104]. More direct evidence for histone mod-
iﬁcations in diabetes was suggested in a report, which showed
that mice deﬁcient in Jhdm2a, an H3K9me2 demethylase,
exhibited features of the metabolic syndrome [105]. A recent
genome-wide analysis of histone modiﬁcations revealed a
global snapshot of the islet chromatin, and several islet-
speciﬁc enhancers were identiﬁed. Interestingly, many of
them were located in genetic loci previously associated
with T2D [106]. HDACs were also shown to regulate the
acetylation of several transcription factors involved in adipo-
cyte differentiation, suggesting an important role for non-HKAc
in metabolic disorders [107,108]. However, the role of HDACs
in epigenetic mechanisms involved in diabetes complica-
tions and the potential use of HDAC inhibitors are not well
studied.
Aberrant promoter histone modiﬁcations can be triggered by
HG and other diabetogenic agents to affect adversely the expres-
sion of key target genes associated with complications. Several
studies have examined the role of histone PTMs in the regulation
of inﬂammatory gene expression in ECs, monocytes, VSMCs, and
renal mesangial cells (MCs), all of which are key cell types
involved in diabetes complications [6,57,109–112]. Endothelial
dysfunction, increased oxidant stress, and reduced nitric oxide
are major features of diabetic micro- and macrovascular compli-
cations. In particular, this is associated with decreased levels or
activity of the endothelial nitric oxide (eNOS) enzyme and is
exempliﬁed in studies involving eNOS knockout mice [109].Diabetes reduces NO bioavailability, resulting in increased EC
proliferation, inﬂammatory gene expression, VSMC activation,
and macrophage inﬁltration, which are the key factors in the
development of DN [109,110]. EC-speciﬁc expression of eNOS
involves formation of an open chromatin near the eNOS promoter
marked by increased H3/H4KAc and H4Kme [113,114]. Interest-
ingly, hypoxia, a known mediator of EC dysfunction and a
potential risk factor for DN [115], also inhibits eNOS expression
through reversal of these promoter-speciﬁc histone modiﬁcations
[116]. Other studies have shown that gene expression in mono-
cytes andmacrophages is also regulated by histonemodiﬁcations,
which play key roles in inﬂammation and macrophage polariza-
tion [57,117]. JMJD3, an H3K27me3 demethylase, and HDAC11
appear to play important regulatory roles in these events
[118–120]. HG-induced inﬂammatory gene expression was asso-
ciated with increased promoter H3/H4KAc, and enhanced recruit-
ment of HATs CBP/P300 as well as the proinﬂammatory
transcription factor NF-kB in THP-1 monocytes. Furthermore,
monocytes from diabetic patients exhibited enhanced H3KAc at
the promoters of key inﬂammatory genes, conﬁrming in vivo
relevance [121]. SET7, an H3K4 methyltransferase, was impli-
cated in NF-kB-mediated inﬂammatory gene expression in TNF-
a-treated THP-1 monocytes, and in macrophages from diabetic
mice [122]. Proﬁling studies using ChIP linked to microarrays
(ChIP-on-chip) revealed key differences in the patterns of repres-
sive (H3K9me2) and active (H3K4me2) histone modiﬁcations at
coding regions of HG-regulated genes in THP-1 monocytes, with
in vivo relevance being shown in primary monocytes from
diabetes patients [123]. Furthermore, comparative ChIP-on-chip
epigenome proﬁling of lymphocytes from T1D patients with
those from normal control volunteers revealed signiﬁcant altera-
tions in H3K9me2 at a subset of genes related to T1D and closely
associated with autoimmune functions and inﬂammation [124],
further demonstrating the role of histone modiﬁcations in
diabetes and its complications. Recent ChIP-on-chip studies with
chromosome 6 tiling arrays in monocytes of T1D patients versus
normal control individuals revealed key variations in H3K9Ac at
the upstream enhancer regions of two HLA genes whose single
nucleotide polymorphisms (SNPs) are known to be closely related
with T1D [125], suggesting potential connections between
genetic SNPs and surrounding epigenetic marks in the etiology
of diabetes.
Emerging evidence supports a role for histone modiﬁca-
tions in the regulation of key genes associated with DN. In a
rat model of T2D-induced DN, hyperglycemia in the kidneys
was associated with reduced levels of active chromatin marks
H3KAc and Ser10 phosphorylation at the ﬁbrillin 1 and
collagen type III alpha1 gene promoters [126]. Changes in
global histone modiﬁcations were seen in the kidneys of
uninephrectomized diabetic db/db mice [127]. Furthermore,
HDAC2 activity was increased in kidneys of diabetic animals,
and inhibition of HDAC activity blocked diabetes-induced
ﬁbrotic gene expression [128]. Recently, evidence of epige-
netic mechanisms in HG- and TGF-b1-induced ﬁbrotic gene
expressions in renal MCs was demonstrated for the ﬁrst time
[129]. In these studies, the induction of key proﬁbrotic genes
by HG and its downstream effectors TGF-b1 was associated
with increases in activation marks (H3K4me-1, H3K4me-2,
and H3K4me-3) and decreases in repressive marks (H3K9me-
1 and H3K9me-2) at these gene promoters. Furthermore, HG
and TGF-b1 could induce the expression of SET7, while SET7
gene silencing inhibited TGF-b1-induced expression of ﬁbro-
tic genes. Interestingly, pretreatment with TGF-b1 antibodies
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Figure 3. Role of TGF-b in HG-mediated histone modiﬁcations and
ﬁbrotic gene expression in mesangial cells. HG and its downstream
effector TGF-b promote open chromatin formation at ﬁbrotic gene
promoters through inhibition of repressive marks (H3K9me) and
increasing activation marks (H4Kme) via regulation of HMTs such as
SET7. This leads to an increase in chromatin access to transcription TFs
and in the expression of ﬁbrotic genes such as PAI-1, Col1a1, and CTGF.
These HG-induced alterations in epigenetic mechanisms and proﬁbro-
tic gene expression can be blocked by TGF-b antibodies. Potential role
of other histone modiﬁcations such as H3K9Ac and coactivator HATs is
also shown. HAT, histone acetyltransferase; HG, high glucose; HMT,
histone methyl transferase; TF, transcription factor; TGF-b, transform-
ing growth factor-b1.
Kidney Res Clin Pract 31 (2012) 139–150 145signiﬁcantly inhibited HG-induced proﬁbrotic gene expres-
sion and alterations in histone modiﬁcations at their promo-
ters [129]. These results demonstrate the involvement of
histone PTMs in HG- and TGF-b1-induced genes relevant to
DN (Fig. 3).
Role of histone modiﬁcations was also demonstrated in
some nondiabetic kidney diseases. Thus, reports showed that
aldosterone can reverse Dot1a-mediated promoter repressive
H3K79me mark to increase the expression of the epithelial Na
(þ) channel alpha (ENaCa) gene in the renal collecting ducts
[130,131]. In other studies, increased expression of inﬂamma-
tory genes such as MCP-1 in a model of renal ischemic injury
was associated with increased H3K4me3 and recruitment of the
chromatin remodeling enzyme Brahma-related gene-1 (BRG1) at
these gene promoters [132]. Changes in repressive histone PTMs
were associated with collagen III gene expression in aging-
induced nephropathy [133]. Notably, epigenetic mechanisms
have been implicated in renal development and maintenance of
podocyte-differentiated function [134,135]. Together, these data
demonstrate that histone PTMs are involved in the regulation of
genes associated with chronic as well as acute renal injuries, and
even with renal development. However, such candidate-gene-
based approaches can only provide a glimpse of a complex
epigenetic landscape. Genome-wide high-throughput proﬁling
approaches can help provide valuable information about the
state of the epigenome in DN.
Recent studies using cell and animal models have sug-
gested that histone modiﬁcations might be associated with
metabolic memory. In one study, there was enhanced inﬂam-
matory gene expression in VSMCs cultured from T2D db/db
mice for several passages relative to those from genetic
control db/þ mice, and this was associated with persistently
reduced H3K9me3 and occupancy of corresponding methyl
transferase Suv39h1 at inﬂammatory gene promoters [78].
Furthermore, there was also reduced levels of Suv39h1 in the
diabetic db/db VSMCs, which was found to be due to an
increased expression of the microRNAs miR-125b that targets
Suv39h1 [136]. The miR-125b mimics could reduce Suv39h1
levels, upregulate inﬂammatory genes in nondiabetic cells,
and also promote monocyte binding in db/þ VSMCs to induce
a diabetic phenotype. This demonstrates a novel cross-talk
between microRNAs and epigenetic mechanisms in diabetic
vascular inﬂammation and metabolic memory. In another
model of metabolic memory, short-term exposure of ECs to
HG led to persistently increased expression of p65 (active
subunit of NF-kB) and inﬂammatory genes for several days
even after returning to normal glucose. This was associated
with higher promoter levels of H3K4me1 and occupancy of
the corresponding SET7 H3K4 methyl transferase [76,137]. A
key role for oxidant stress in promoting metabolic memory in
ECs was suggested in this and other studies [74,76,99].
Interestingly, in a rat model of diabetic retinopathy and
metabolic memory, retinal ECs exhibited reduced expression
of sod gene that codes for the protective antioxidant protein
superoxide dismutase. This was associated with increased
levels of the repressive mark H4K20me3 and occupancy of the
corresponding methyltransferase Suv420h at the sod gene
promoter, leading to repression of superoxide dismutase [83].
Together, these studies support a key role for histone mod-
iﬁcations in metabolic memory of diabetic vascular complica-
tions that seem to persist despite glycemic control (Fig. 2).
Since renal MCs, tubular epithelial cells, ECs, and podocytes
are also affected by HG and diabetes, similar mechanisms inthese cells in vivo might also contribute to metabolic memory
of DN. Moreover, it has recently been speculated that epige-
netic mechanisms may also regulate hypertension, which is
associated with both diabetic and nondiabetic renal diseases
and can persist across generations [138].Resources and technologies for epigenomics research
in diabetes and its complications
The National Institutes of Health Roadmap Epigenomics
Program is focused on mapping the locations and characterizing
the functions of epigenetic modiﬁcations in normal and diseased
states using numerous cell types and tissues. These epigenomic
maps are being made available to the entire scientiﬁc commu-
nity (http://www.ncbi.nlm.nih.gov/epigenomics) and will be a
tremendous resource for future research. Recent advances in
next-generation sequencing and related technologies as well as
in bioinformatics tools have accelerated epigenomics research
signiﬁcantly [25,139,140]. These include ChIP-on-chip and ChIP-
Seq to study genome-wide patterns of histone modiﬁcations
[25,57,139,141]. DNAMe is traditionally studied using bisulﬁte
conversion of 50-methyl cytosine or approaches to enrich
methylated DNA [142,143]. These are coupled to microarrays
or next-generation DNA-Seq analysis to determine genome-
wide distribution of DNAMe [57,144]. Novel features of the
epigenome, including key regulatory elements/regions, have
been uncovered from the combinatorial and integrative analyses
of genome-wide patterns of histone PTMs and DNAMe along
with transcriptome analyses of gene expression patterns
[25,42,50,51,140,145]. These technologies are gradually being
utilized to decipher the epigenomes of key target cells involved
in diabetes and its complications. Utilization of these genome-
wide proﬁling technologies to study renal biopsies or genomic
DNA from patients with DN or other renal diseases relative to
MA Reddy et al / Epigenetic modiﬁcations and diabetic nephropathy146normal control individuals can yield signiﬁcant information
regarding the epigenome of normal versus diseased kidneys,
which in turn could open the doors for the development of
novel therapeutic opportunities. However, it is also important to
consider conducting such studies on cells or tissues that
manifest the disease, since the epigenome is cell-type speciﬁc.
This could pose a challenge in renal research due to the multi-
cellular nature of the kidney.Summary
Increasing evidence supports the critical role of hypergly-
cemia and downstream mediators such as AGEs, Ang II, and
TGF-b in signaling, molecular, and chromatin-based mechan-
isms in the development of metabolic memory and diabetic
complications (Fig. 2). However, diabetes leads to multiorgan
dysfunction and is associated with several physiological
abnormalities, including insulin resistance and dyslipidemia
(T2D) and autoimmune disorders (T1D). It is further compli-
cated by dietary choices and the lifestyles. Although numer-
ous studies have examined the role of genetic variants in the
pathology of diabetes complications such as DN, very few
candidate loci with functional associations have been uncov-
ered. Given the strong inﬂuence of environmental factors, the
additional role of epigenetics is worth considering. Further-
more, metabolic memory still remains a major obstacle in the
treatment and prevention of diabetes complications. Recent
advances in high-throughput genomic sequencing approaches
should make it feasible to better understand the epigenome
state in diabetes and related complications such as DN.
Importantly, they might reveal key differences in the epigen-
ome between patients who progress to DN and other com-
plications and those who do not. Unlike genetic changes,
epigenetic changes are reversible, which thus provides
a window of opportunity for therapeutic development.
Several epigenetic regulators such as inhibitors of DNAMe,
HDACs, HATs, and DNMTs are already being used for
cancer treatment, and some are being evaluated for vascular
disorders such as restenosis [35,47,146,147]. Recent studies
showing reversal of epigenetic modiﬁcations associated with
islets [103], ECs [113], monocytes [148], and renal cells
[128,129,149] indicate that epigenetic therapy for diabetic
complications is a distinct possibility. Further work in this
rapidly expanding area of research could advance our knowl-
edge of epigenetic mechanisms involved in the pathogenesis
of DN and other diabetic complications, which in turn could
lead to new therapeutic strategies.Conﬂict of interest
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